Navigation Links
Use of antidepressant does not improve symptoms from stomach disorder
Date:12/24/2013

Among patients with idiopathic (of unknown cause) gastroparesis, use of the antidepressant nortriptyline compared with placebo for 15 weeks did not result in improvement in overall symptoms, according to a study appearing in the December 25 issue of JAMA. Gastroparesis is a disease of the muscles of the stomach or the nerves controlling the muscles that causes the muscles to stop working, which can result in inadequate grinding of food by the stomach and poor emptying of food from the stomach into the intestine.

Gastroparesis remains a challenging syndrome to manage, with few effective treatments and a lack of rigorously controlled trials. One possible approach to treatment is based on the hypothesis that some of the symptoms (e.g., nausea, pain) arise because of changes in certain nerves. Tricyclic antidepressants are a category of drug often used to treat refractory (not yielding readily to treatment) symptoms of nausea, vomiting, and abdominal pain, according to background information in the article.

Henry P. Parkman, M.D., of Temple University, Philadelphia, and colleagues randomized 130 patients with idiopathic gastroparesis to nortriptyline (n = 65) or placebo (n = 65) to determine whether treatment with the tricyclic antidepressant nortriptyline would result in improvement of symptoms. Study drug dose was increased at 3-week intervals. The primary outcome measure was a decrease in the patient's Gastroparesis Cardinal Symptom Index (GCSI) score of at least 50 percent on 2 consecutive visits during 15 weeks of treatment.

The researchers found that the proportion of patients experiencing symptomatic improvement on 2 visits did not differ between the treatment groups: 15 (23 percent) in the nortriptyline group vs. 14 (21 percent) in the placebo group. There were also no treatment group differences in measures of nausea, fullness or early satiety, or bloating. Treatment was stopped more often in the nortriptyline group (29 percent) than in the placebo group (9 percent), but numbers of adverse events were not different.

"Our results raise general doubts about the utility of tricyclic antidepressants in low doses as a strategy for the treatment of idiopathic gastroparesis," the authors conclude.


'/>"/>

Contact: Kathleen Duffy
Kathleen.Duffy@tuhs.temple.edu
267-800-4359
The JAMA Network Journals
Source:Eurekalert

Related medicine news :

1. Minorities, Medicare Recipients Less Likely to Get Antidepressants
2. Newer Antidepressants May Be Safe for Parkinsons Patients
3. Publication Bias Casts Doubt on Value of Antidepressants for Autism
4. Antidepressant use associated with increased mortality among critically ill patients?
5. Medicare Coverage Gap May Cause Seniors to Forgo Antidepressants
6. Mayo Clinic: Antidepressant eases radiation-related mouth pain in head, neck cancer
7. Common Antidepressants Too Risky During Pregnancy, Researchers Say
8. Common Antidepressants Tied to Higher Bleeding Risk in Warfarin Users: Study
9. When Antidepressants Dont Work, Give Counseling a Try
10. Experimental Antidepressant Appears Quick-Acting, Safe
11. Study shows antidepressant could do double duty as diabetes drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2020)... ... , ... Denials Management, Inc. has just published The Health Insurance Appeals Guide ... denials of mental health and substance use disorder (MH/SUD) treatment services. It was written ... explain the steps in the appeals process. Complimentary copies of the Guide can ...
(Date:6/24/2020)... ... ... Dr. Katinka van der Merwe, the creator of the world’s leading 12 week ... Grace podcast. She explains her outside-the-box, holistic approach to treating CRPS and how important ... diagnosed with CRPS about 10 years ago, Amberly Lago , the host of ...
(Date:6/24/2020)... , ... June 24, 2020 , ... Skyroam , ... a partnership with LabWare , the leading provider of enterprise software for testing ... connectivity as part of LabWare’s new Portable Disease Surveillance Lab (PDSL) kit. , “Stopping ...
(Date:6/23/2020)... ... 2020 , ... Anesthesia Progress —Receiving dental care during ... virus, which is primarily found in oral, nasal, and pharyngeal mucosa and in ... or by aerosols produced during aerosol-generating procedures (AGPs). Given the transmission type, four ...
(Date:6/23/2020)... ... June 22, 2020 , ... In its latest ... and forecasts for the market for tests tied to therapeutic selection or effectiveness. ... in hospitals, as well as pharmaceutical companies serving them to determine recent market trends. ...
Breaking Medicine News(10 mins):
(Date:7/2/2020)... ... ... Exercise.com, the fitness industry’s leading tech company specializing in all-in-one business software ... software during the months of May and June. This announcement highlights the growing demand ... gym giants like 24 Hour Fitness and Gold’s Gym are ...
(Date:7/2/2020)... SPRINGS, Miss. (PRWEB) , ... July 02, 2020 ... ... Springs, Mississippi-based wholesale pharmaceutical distributor, is pleased to announce its donation of more ... and the Michigan Department of Health and Human Services. As extreme medical shortages ...
(Date:7/1/2020)... ... 01, 2020 , ... Lumeda Inc. (“Lumeda”), a ... formation of its Scientific Advisory Board with the appointment of a panel of ... to support company development and introduction of its PDT products to the clinic. ...
Breaking Medicine Technology: